Portal de Periódicos da CAPES

Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients – “En route for eradication”?

2017; Elsevier BV; Volume: 75; Issue: 3 Linguagem: Inglês

10.1016/j.jinf.2017.05.008

1532-2742

Pierre Pradat, Pascal Puglièse, Isabelle Poizot‐Martin, Marc‐Antoine Valantin, Lise Cuzin, Jacques Reynes, Eric Billaud, Thomas Huleux, Firouzé Bani‐Sadr, David Rey, A. Frésard, Christine Jacomet, Claudine Duvivier, Antoine Chéret, Laurent Hustache‐Mathieu, Bruno Hoën, André Cabie, Laurent Cotte, Laurent Cotte, Christian Chidiac, Tristan Ferry, Florence Ader, F. Biron, A. Boibieux, P. Miailhes, T. Perpoint, I. Schlienger, John Lippmann, Elisabeth Braun, J. Koffi, Christophe Longuet, V. Guéripel, C. Augustin-Normand, C. Brochier, S Degroodt, P. Puglièse, C. Ceppi, Éric Cua, Jacqueline Cottalorda, Johan Courjon, P. Dellamonica, Élisa Demonchy, Anne De Monte, J. Durant, C Etienne, Stephen J. Ferrando, J.G. Fuzibet, R. Garraffo, A. Joulié, Karine Risso, V. Mondain, A. Naqvi, N. Oran, I. Perbost, Stéphane Pillet, B Prouvost-Keller, S Wehrlen-Pugliese, E. Rosenthal, S. Sausse, V. Rio, P.-M. Roger, Sylvie Brégigeon, Olivia Zaegel‐Faucher, V. Obry‐Roguet, M Orticoni, M J Soavi, P Geneau de Lamarlière, Hélène Laroche, E. Ressiot, Mauro Giovanni Carta, M.J. Ducassou, Ingrid Jacquet, S. Gallie, Anne Galinier, A.S. Ritleng, A Ivanova, Carla Blanco-Betancourt, C. Lions, C. Debreux, V. Obry‐Roguet, Isabelle Poizot‐Martin, Rachid Agher, Christine Katlama, Marc‐Antoine Valantin, Claudine Duvivier, O. Lortholary, Fanny Lanternier, Caroline Charlier, C. Rouzaud, Claire Aguilar, Bonnie Henry, David Lebeaux, G. Cessot, Anna Gergely, Paul‐Henri Consigny, F. Touam, C Louisin, Marco Antonio Álvarez, N. Biezunski, Lise Cuzin, Alexa Debard, Pierre Delobel, Cyrille Delpierre, C. R. Fourcade, B. Marchou, Guillaume Martin‐Blondel, M. Porte, M Mularczyk, D. Garipuy, Karine Sauné, I. Lepain, M. Marcel, E. Puntis, N. Atoui, Marie-Laure Casanova, V. Faucherre, Jeanne‐Marie Jacquet, V. Le Moing, Alain Makinson, Corinne Merle De Boever, A Montoya Ferrer, Christina Psomas, Jacques Reynes, F. Raffi, Clotilde Allavena, Eric Billaud, Charlotte Biron, B. Bonnet, S. Bouchez, D. Boutoille, C. Brunet, T Jovelin, Nancy Hall, C. Bernaud, P Morineau, Véronique Reliquet, O Aubry, P Point, M. Besnier, L Larmet, H Hüe, S. Pineau, Elisabeth André‐Garnier, A. Rodallec, Ph. Choisy, S. Vandame, T. Huleux, F. Ajana, I. Alcaraz, V. Baclet, T. Huleux, H. Melliez, N. Viget, M. Valette, E. Aïssi, Ch. Allienne, Agnès Meybeck, Bertrand Riff, Firouzé Bani‐Sadr, C. Rouger, J. Berger, Yohan N’Guyen, D. Lambert, I. Kmiec, Maxime Hentzien, Delphine Lebrun, Caroline Migault, D. Rey, M.L. Batard, Claudine Bernard-Henry, Geneviève Chêne, E de Mautort, Patricia Fischer, M Partisani, M. Priester, F. Lucht, A. Frésard, Élisabeth Botelho-Nevers, Amandine Gagneux‐Brunon, C. Cazorla, C. Guglielminotti, F. Daoud, Martin Lutz, Christine Jacomet, H. Laurichesse, O. Lesens, M. Vidal, Natacha Mrozek, V. Corbin, C. Auméran, Olivier Baud, S. Casanova, Dilek Çoban, Laurent Hustache‐Mathieu, M.C. Thiebaut-Drobacheff, Adeline Foltzer, V. Gendrin, F Bozon, C Chirouze, Sylvie Abel, André Cabie, Raymond Césaire, G. Dos Santos, Laurence Fagour, Fatiha Najioullah, M. Ouka, S. Pierre-François, Mathilde Pircher, B. Rozé, Bruno Hoën, Rachida Ouissa, I. Lamaury,

Liver Disease Diagnosis and Treatment

Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfected patients.All HIV-HCV patients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection.Among 32,945 HIV-infected patients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR.HCV treatment dramatically increased in HIV-HCV patients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIV patients will drastically decrease in the forthcoming years.